#BEGIN_DRUGCARD DB01326

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Mandol

# CAS_Registry_Number:
34444-01-4

# ChEBI_ID:
3480

# Chemical_Formula:
C18H18N6O5S2

# Chemical_IUPAC_Name:
(6R,7R)-7-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-06-30 11:22:18 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Cefamandole (INN, also known as cephamandole) is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States.

# Dosage_Forms:
Solution	Parenteral

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Amikacin	Increased risk of nephrotoxicity
Gentamicin	Increased risk of nephrotoxicity
Netilmicin	Increased risk of nephrotoxicity
Probenecid	Probenecid may increase the serum level of cefamandole.
Tobramycin	Increased risk of nephrotoxicity

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.50

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cefamandole

# HET_ID:
Not Available

# Half_Life:
The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.

# InChI_Identifier:
InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1

# InChI_Key:
InChIKey=OLVCFLKTBJRLHI-AXAPSJFSSA-N

# Indication:
For the treatment of serious infections caused by susceptible strains of  microorganisms.

# KEGG_Compound_ID:
C06879

# KEGG_Drug_ID:
D02344

# LIMS_Drug_ID:
1326

# Mechanism_Of_Action:
Like all beta-lactam antibiotics, cefamandole binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefamandole interferes with an autolysin inhibitor.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
462.503

# Molecular_Weight_Mono:
462.078009096

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448837

# Pharmacology:
Cefamandole is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. The bactericidal action of cefamandole results from inhibition of cell-wall synthesis. Cephalosporins have in vitro activity against a wide range of gram-positive and gram-negative organisms.

# Predicted_LogP_Hydrophobicity:
-0.05

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
5.81e-01 g/l

# Primary_Accession_No:
DB01326

# Protein_Binding:
75%

# PubChem_Compound_ID:
456255

# PubChem_Substance_ID:
46508882

# RxList_Link:
http://www.rxlist.com/cgi/generic/cefamandole.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Cefadole
Cefamandole nafate

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.

# Update_Date:
2013-02-08 16:20:05 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cefamandole

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
3266730	Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AP006841

# Drug_Target_1_GenBank_ID_Protein:
52214157

# Drug_Target_1_GeneCard_ID:
pbpA

# Drug_Target_1_Gene_Name:
pbpA

# Drug_Target_1_Gene_Sequence:
>528 bp
ATGCGAAAATTGAAAATAACCGAGCTGAACCGGATAAGTATAGAAGAGTTTAAAGAAGCT
GATAAATTGCCTTTAGTTGTAGTGTTGGACGATATACGGAGTTTGCATAATATCGGTTCT
GTGTTTCGTACGGCAGATGCTTTCCGGATTGAATGTATTTATCTGTGTGGAATTACGGCT
ACTCCTCCCCATCCCGAGATGCATAAGACAGCTTTGGGAGCCGAGTTTACAGTGGATTGG
AAGTATGTTAATAACGCAGTTGAAACGGTTGATAACCTCCGGAGTGAAGGATATGTGGTA
TACTCTGTCGAACAGGCGGAGGGGAGTATCATGTTGGATGAGTTAACACTGGACCGTTCG
AAGAAATATGCTGTAGTTATGGGAAATGAAGTAAAAGGAGTGCAGCAGGAGGTTATTGAC
CATTCGGATGGTTGTATTGAGATTCCCCAATATGGCACAAAACATTCATTGAATGTATCG
GTAACAGCAGGAATTGTGATCTGGGATTTATTTAAAAAGTTGAAATAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
15466707	Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N, Kuhara S, Hattori M, Hayashi T, Ohnishi Y: Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14919-24. Epub 2004 Oct 4.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6187

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
69434.3

# Drug_Target_1_Name:
Penicillin-binding protein 2

# Drug_Target_1_Number_of_Residues:
618

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2
MAKDYVLEKRKYVIGGVALAIVLIYLLRLFSLQIATDDYKKNADSNAFLNKIQYPSRGAM
YDRNDKLLVFNQPAYDITMVPKEVENLDTLDLCQTLNITRAQFLKIMSDMKDRRRNPGYS
RYTNQVFMSQLSAEECGVFQEKLFKFHGFYIQRRTIRQYSYNSAAHVLGDIGEVSMKDIE
NDDYYIRGDYIGKQGIEKSYESYLRGEKGVEVLLRDAHGRIQGHYMDGKYDKRPIPGKNL
KLGIDIDLQMLGERLLKNKIGSIVAIEPETGEILCMVSSPDFDPRLMIGRQRGKNHLMLQ
RDPMKPLLNRSIMGVYPPGSTFKTAQALTFLQEGIIQTNTPAFPCAHGFNYGSLHVGCHA
HGSPLPLIPAIATSCNSYFCWGLFRMFGDRKYGSSQNAITVWKDHMVSQGFGYKLGVDLP
GEKRGLIPNAQFYDKAYRGRWNGLTVISIAIGQGEILATPLQIANLGATIANRGHFITPH
IVKEIQDEQLDSLYRVPRKTSIDRKHYEDVVTGMRAAVTGGTCRVAGAILPDVEVCGKTG
TAQNRGHDHSVFMGFAPMNNPKIAIAVYVENGGFGAVYGVPIGALMMEQYLKGKLSPENE
IRAEEYSNRVIMYGNEER

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q70KI2

# Drug_Target_1_SwissProt_Name:
Q70KI2_BACFR

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
8.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01326
